Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study  by Gurwith, Marc et al.
238 www.thelancet.com/infection   Vol 13   March 2013
Articles
Safety and immunogenicity of an oral, replicating adenovirus 
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Summary
Background Replication-competent virus vector vaccines might have advantages compared with non-replicating vector 
vaccines. We tested the safety and immunogenicity of an oral adenovirus serotype 4 vector vaccine candidate (Ad4-
H5-Vtn) expressing the haemagglutinin from an avian inﬂ uenza A H5N1 virus.
Methods We did this phase 1 study at four sites in the USA. We used a computer-generated randomisation list (block 
size eight, stratiﬁ ed by site) to assign healthy volunteers aged 18–40 years to receive one of ﬁ ve doses of Ad4-H5-Vtn 
(10⁷ viral particles [VP], 10⁸ VP, 10⁹ VP, 10¹⁰ VP, 10¹¹ VP) or placebo (3:1). Vaccine or placebo was given on three 
occasions, about 56 days apart. Participants, investigators, and study-site personnel were masked to assignment 
throughout the study. Subsequently, volunteers received a boost dose with 90 μg of an inactivated parenteral H5N1 
vaccine. Primary immunogenicity endpoints were seroconversion by haemagglutination-inhibition (HAI), deﬁ ned as 
a four-times rise compared with baseline titre, and HAI geometric mean titre (GMT). We solicited symptoms of 
reactogenicity daily for 7 days after each vaccination and recorded symptoms that persisted beyond 7 days as adverse 
events. Primary analysis was per protocol. This trial is registered with ClinicalTrials.gov, number NCT01006798.
Findings We enrolled 166 participants (125 vaccine; 41 placebo) between Oct 19, 2009, and Sept 9, 2010. HAI 
responses were low: 13 of 123 vaccinees (11%, 95% CI 6–17) and three of 41 placebo recipients (7%, 2–20) 
seroconverted. HAI GMT was 6 (95% CI 5–7) for vaccinees, and 5 (5–6) for placebo recipients. However, when 
inactivated H5N1 vaccine became available, one H5N1 boost was oﬀ ered to all participants. In this substudy, HAI 
seroconversion occurred in 19 of 19 participants in the 10¹¹ VP cohort (100%; 95% CI 82–100) and eight of 22 
placebo recipients (36%; 17–59); 17 of 19 participants in the 10¹¹ VP cohort (89%; 67–99) achieved seroprotection 
compared with four of 22 placebo recipients (18%; 5–40); GMT was 135 (89–205) with 10¹¹ VP, compared with 13 
(7–21) with placebo. The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three 
vaccinations was signiﬁ cantly higher in vaccinees than placebo recipients (21 [16·8%] of 125 vs one [2·4%] of 41, 
p=0·017; 24 [19·2%] of 125 vs two [4·9%] of 41, p=0·027; 41 [32·8%] of 125 vs six [14·6%] of 41, p=0·028; 
respectively). No serious treatment-related adverse events occurred.
Interpretation Oral Ad4 vector priming might enhance the eﬃ  cacy of poorly immunogenic vaccines such as H5N1.
Funding Wellcome Trust Foundation, PaxVax.
Introduction
Replication-competent (live) vaccine vectors have 
theoretical advantages compared with other vaccine 
approaches, because they combine the improved eﬃ  cacy 
of live-attenuated vaccines with the safety of inactivated 
or subunit vaccines.1 There has been interest in 
replicating viral vectors as candidates for HIV2 or 
ﬁ lovirus3 vaccines, and adenoviruses have been noted as 
having particular beneﬁ ts as potential recombinant-
vector vaccines for inﬂ uenza4 and HIV.5 Only a few 
replicating vector viruses, other than ﬂ avivirus chimeric 
recombinants between related ﬂ aviviruses, have ad-
vanced to phase 1 studies.6–10 Candidate vaccine viruses 
of adenovirus serotypes 4 (Ad4) and 7 (Ad7), when 
bioengineered as replication-competent vectors, have 
the logistical and economic advantages of oral admin-
istration, are non-pathogenic by the oral route,11 remain 
fully replication competent, and, importantly, have 
substantial safety data having been given to more than 
10 million US military recruits without notable adverse 
events.11 In 1991, a small phase 1 study assessed an 
Ad7-hepatitis B vector, but little replication occurred and 
no antibody response to the hepatitis B transgene was 
noted.10
We have developed Ad4 as a replicating vector virus, 
and as the ﬁ rst clinical assessment of this vector platform, 
did a large phase 1 study of an oral Ad4 vector-vaccine 
candidate expressing the haemagglutinin from an avian 
inﬂ uenza A H5N1 virus. Our objectives were to assess 
safety of the vaccine, conﬁ rm that it replicates after oral 
administration, establish whether it expresses the 
haemagglutinin encoded by the transgene, and assess its 
ability to induce haemagglutinin-speciﬁ c systemic and 
mucosal immune responses.
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Methods
Study design and participants
This ascending dose, randomised, double-blind, placebo-
controlled study was done at four sites (two university 
sites and two clinical research centres; appendix) in the 
USA. The study population was healthy men and non-
pregnant women, aged 18–40 years, living with no more 
than two healthy, adult household contacts. We did not 
use baseline Ad4 serostatus as an entry criterion. Study 
participants and all their household contacts provided 
written informed consent and agreed to provide protocol-
speciﬁ ed specimens for clinical laboratory, virological, 
and immunological assays. We obtained separate written 
informed consent from individuals who participated in a 
boost phase. The protocol was approved by institutional 
review boards and institutional biosafety committees at 
the participating centres.
Randomisation and masking
Participants were enrolled in ascending dose cohorts and 
randomised independently within each (3:1) to either 
Ad4-H5-Vtn vaccine or placebo. Randomisation was 
stratiﬁ ed by site, with a masked block size of eight. At 
each site an independent, unmasked pharmacist 
dispensed either vaccine or placebo according to a 
computer-generated randomisation list. Participants, 
household contacts, investigators, study-site personnel, 
and moni tors were masked to participants’ treatment 
assignment through out treatment and follow-up. 
Unmasked admin istration of the boost vaccination was 
oﬀ ered to both vaccine and placebo recipients.
Procedures
The vaccine, Ad4-H5-Vtn, is a recombinant, replication-
competent Ad4, encoding full-length haemagglutinin 
from inﬂ uenza A H5N1 virus (A/Vietnam/1194/2004). 
Its bioengineering and characteristics, including 
genetic stability, have been described elsewhere.12 The 
initial study design required about 96 volunteers to 
receive two vaccinations with one of three doses 
(10⁷ viral particles [VP], 10⁸ VP, or 10⁹ VP) of Ad4-H5-
Vtn or placebo. For reference, the US military Ad4 
vaccine, which is the Ad4 vector backbone, is currently 
dosed at no less than 10⁴·⁵ tissue culture infective dose50 
(roughly equivalent to 10⁷ VP).13 After a blinded review 
showed very little antibody response within the 10⁷ VP, 
10⁸ VP, or 10⁹ VP dose cohorts but no evidence of 
dose-related reacto genicity or toxic eﬀ ects, the protocol 
was amended to add two higher dose groups, 10¹⁰ VP 
and 10¹¹ VP, and administration of a third dose in all 
groups. The additional vaccination and the two higher 
dose groups were incorporated into the ascending 
dose design after approval from an independent data 
monitoring committee. After the inactivated parenteral 
subvirion H5N1 vaccine in the strategic national 
stockpile (A/Vietnam/1203/2004)14 became available, 
the protocol was further amended: all participants not 
lost to follow-up were oﬀ ered a boost with this 
inactivated vaccine.
We solicited symptoms of reactogenicity daily for the 
7 days after each vaccination (appendix); reactogenicity 
symptoms that persisted beyond 7 days were recorded as 
adverse events. Adverse events were recorded by site 
coordinators for at least 180 days after vaccination; 
clinical laboratory assessments were made at baseline 
and 7 days after each vaccination. 
Immunological specimens were blood for Ad4 and 
H5N1 serology and cellular immune assays, and nasal 
and rectal wicks15,16 for assess ment of antibodies in 
mucosal secretions. We obtained specimens before each 
vaccination and at 28 days and 56 days after vaccination 
for Ad4 and H5N1 serology. We obtained cervical and 
rectal wicks15 from a subset of participants who consented 
to additional specimen collection. We assessed blood and 
rectal and throat swabs for Ad4-H5-Vtn by PCR on days 
0, 7, 14, and 28 to assess shedding of vaccine virus or 
possible systemic spread; positive specimens were 
conﬁ rmed by Ad4 culture. We assessed potential 
transmission to house hold contacts by monitoring 
adverse events and by immunological and virological 
assessments: Ad4 and H5N1 serology on the day of each 
vaccination and 56 days later, and real-time (rt)PCR 
analysis of throat and rectal swabs 14 days after each 
vaccination. The rtPCR assay was speciﬁ c for Ad4-H5-
Vtn and would not be positive for wild-type Ad4. Any 
participant or household contact who developed signs or 
symptoms of illness compatible with clinical adenovirus 
infection was examined and appropriate clinical 
specimens (eg, urine or conjunctival swab), throat and 
rectal swabs, and blood were examined with rtPCR.
Serum haemagglutination-inhibition (HAI),17 micro-
neutralisation18 for H5N1 (A/Vietnam/1194/2004) anti-
body, and neutralising antibody response to Ad419 were 
assayed before and 28 days and 56 days after each 
vaccination. Additionally, H5 haemagglutinin-speciﬁ c IgG 
and IgA ELISAs were done in plasma20 and in mucosal 
secretions.13 T-cell responses to haemagglutinin and Ad4 
antigens were assessed in interferon-γ and interleukin-2 
enzyme-linked immunosorbent spot (ELISPOT) assays21 
with peripheral blood mononuclear cells stimulated with 
recombinant H5N1 haemagglutinin protein, for each of 
four pools of overlapping haem agglutinin peptides, or 
inactivated Ad4. Ad4-H5-Vtn virus in throat swabs, rectal 
swabs, and blood samples or clinical specimens was 
assessed by speciﬁ c rtPCR (appendix).
Statistical analysis
Two primary immunogenicity endpoints were pre-
speciﬁ ed: seroconversion by HAI, deﬁ ned as a four-times 
rise compared with baseline titre, and HAI geometric 
mean titre (GMT). A sample size of 24 vaccine recipients 
per treatment group would give 76% power to detect a 
two-times diﬀ erence in the occurrence of HAI 
seroconversion between any two treatment groups, with 
For the trial protocol see 
http://www.paxvax.com/h5n1
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a two-sided Fisher’s exact test with α=0·05 and assuming 
the occurrence in the better performing group was at 
least 80%. Primary analysis was per protocol, which 
required participants to have both a pre-vaccination and 
at least one post-vaccination HAI response.  
We summarised categorical endpoints as percentages 
and 95% CIs, and compared them with Fisher’s exact 
test. Continuous HAI, microneutralisation, and Ad4 
neutralisation data were summarised as geometric 
means and CIs and compared with a t test on log-
transformed data; ELISA and ELISPOT data were 
summarised as medians and IQRs and compared with 
the Wilcoxon signed-rank test. We used post-
randomisation stratiﬁ cation to analyse the eﬀ ect of 
baseline Ad4 seropositivity. Safety was sum marised for 
all participants who received at least one vaccination 
with either Ad4-H5-Vtn or placebo; immunological 
analyses were done for subsets of parti cipants who had 
results from before and after vaccination.
This trial is registered with ClinicalTrials.gov, number 
NCT01006798.
Role of the funding source
The Wellcome Trust had no role in the study design or 
interpretation of data. The sponsor (PaxVax) designed the 
protocol in collaboration with participating inves tigators, 
and had overall responsibility for the conduct of the 
study. All authors vouch for accuracy and com pleteness 
of data. MG, ML, and ET had complete access to all data; 
all authors could access any of the data on request. Data 
were analysed by the biostatistician (ML), and the 
manuscript drafted by the ﬁ rst author (MG) with input 
from all authors.
Results
We enrolled 166 participants (125 vaccine recipients and 
41 placebo recipients) between Oct 19, 2009, and Sept 9, 
2010. Participants who were enrolled in the ﬁ ve vaccine 
24 received vaccination 1: 
      107 VP vaccine
1 discontinued
    1 moved
23 received vaccination 2: 
      107 VP vaccine
6 discontinued*
    6 declined third
        vaccination†
17 received vaccination 3: 
      107 VP vaccine
5 discontinued
    1 lost interest
    1 other reason
    3 unable to
       contact
13 received boost vaccination
      Includes 1 with only 
      2 vaccinations
25 received vaccination 1: 
      1011 VP vaccine
1 discontinued
    1 moved
    1 change in
        household
23 received vaccination 2: 
      1011 VP vaccine
3 discontinued*
    1 scheduling
       problem
    2 lost to
    follow-up
20 received vaccination 3: 
      1011 VP vaccine
2 discontinued
    1 moved
    1 lost to 
        follow-up
19 received boost vaccination
      Includes 1 with only 
      2 vaccinations
24 received vaccination 1: 
      1010 VP vaccine
5 discontinued
    2 moved
    1 pregnancy
    1 felt anxious
    1 change in
        household
19 received vaccination 2: 
      1010 VP vaccine
1 discontinued
    1 pregnancy
18 received vaccination 3: 
      1010 VP vaccine
 3 discontinued
     1 other reason
     2 unable to
         contact
15 received boost vaccination
27 received vaccination 1: 
      109 VP vaccine
27 received vaccination 2: 
      109 VP vaccine
3 discontinued
    1 on excluded
       medication
    2 lost to 
       follow-up
24 received vaccination 3: 
      109 VP vaccine
6 discontinued
    2 were too busy
    1 ineligible
    2 other reasons
    1 unable to
        contact
18 received boost vaccination
25 received vaccination 1: 
      108 VP vaccine
25 received vaccination 2: 
      108 VP vaccine
1 discontinued*
    1 declined third
        vaccination†
24 received vaccination 3: 
      108 VP vaccine
7 discontinued
    1 moved
    2 ineligible
    4 unable to
       contact
18 received boost vaccination
      Includes 1 with only 
      2 vaccinations
41 received vaccination 1: 
      placebo
1 discontinued
    1 lost to follow-up
40 received vaccination 2: 
      placebo
9 discontinued*
    1 moved
    1 lost interest
    1 noncompliance
    2 on excluded
        medication
    1 pregnancy
    1 declined third
        vaccination†
    2 lost to follow-up
31 received vaccination 3: 
      placebo
11 discontinued
      3 moved
      2 lost interest
      2 were too busy
      1 pregnancy
      1 unable to
         contact
     2 lost to follow-up
22 received boost vaccination
      Includes 2 with only 
     2 vaccinations
Figure 1: Trial proﬁ le
Vaccination refers to oral administration of Ad4-H5-Vtn or oral placebo; boost vaccination refers to parenteral administration of subvirion inactivated H5N1 vaccine. Discontinuation means that a 
participant either dropped out of the study, or stopped vaccinations but continued follow-up. *Some participants who discontinued or missed vaccinations later received the boost vaccination. †Early 
entrants to the study were required to sign an additional consent form to receive the third vaccination but some declined to do so.
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Ad4-H5-Vtn vaccine recipients Placebo (n=41)
10⁷ VP (n=24) 10⁸ VP (n=25) 10⁹ VP (n=27) 10¹⁰ VP (n=24) 10¹¹ VP (n=25) All doses combined 
(n=125)
Abdominal pain
Any 2 (8·3%) 3 (12·0%) 4 (14·8%) 3 (12·5%) 1 (4·0%) 13 (10·4%) 1 (2·4%)
Mild 1 (4·2%) 3 (12·0%) 2 (7·4%) 3 (12·5%) 1 (4·0%) 10 (8·0%) 1 (2·4%)
Moderate 1 (4·2%) 0 2 (7·4%) 0 0 3 (2·4%) 0
Severe 0 0 0 0 0 0 0
Diarrhoea
Any 2 (8·3%) 3 (12·0%) 3 (11·1%) 5 (20·8%) 4 (16·0%) 17 (13·6%) 2 (4·9%)
Mild 2 (8·3%) 3 (12·0%) 0 3 (12·5%) 4 (16·0%) 12 (9·6%) 2 (4·9%)
Moderate 0 0 3 (11·1%) 2 (8·3%) 0 5 (4·0%) 0
Severe 0 0 0 0 0 0 0
Nausea or vomiting
Any 1 (4·2%) 1 (4·0%) 3 (11·1%) 1 (4·2%) 3 (12·0%) 9 (7·2%) 1 (2·4%)
Mild 1 (4·2%) 1 (4·0%) 1 (3·7%) 1 (4·2%) 3 (12·0%) 7 (5·6%) 1 (2·4%)
Moderate 0 0 2 (7·4%) 0 0 2 (1·6%) 0
Severe 0 0 0 0 0 0 0
Chills
Any 0 1 (4·0%) 0 1 (4·2%) 0 2 (1·6%) 0
Mild 0 1 (4·0%) 0 0 0 1 (0·8%) 0
Moderate 0 0 0 1 (4·2%) 0 1 (0·8%) 0
Severe 0 0 0 0 0 0 0
Muscle or body aches
Any 1 (4·2%) 1 (4·0%) 4 (14·8%) 2 (8·3%) 3 (12·0%) 11 (8·8%) 1 (2·4%)
Mild 0 1 (4·0%) 2 (7·4%) 1 (4·2%) 3 (12·0%) 7 (5·6%) 1 (2·4%)
Moderate 1 (4·2%) 0 2 (7·4%) 1 (4·2%) 0 4 (3·2%) 0
Severe 0 0 0 0 0 0 0
Joint pain
Any 1 (4·2%) 0 2 (7·4%) 1 (4·2%) 1 (4·0%) 5 (4%) 1 (2·4%)
Mild 1 (4·2%) 0 1 (3·7%) 0 1 (4·0%) 3 (2·4%) 0
Moderate 0 0 1 (3·7%) 1 (4·2%) 0 2 (1·6%) 1 (2·4%)
Severe 0 0 0 0 0 0 0
Tiredness
Any 6 (25·0%) 7 (28·0%) 6 (22·2%) 5 (20·8%) 4 (16·0%) 28 (22·4%) 5 (12·2%)
Mild 2 (8·3%) 4 (16·0%) 1 (3·7%) 2 (8·3%) 4 (16·0%) 13 (10·4%) 2 (4·9%)
Moderate 4 (16·7%) 3 (12·0%) 4 (14·8%) 3 (12·5%) 0 14 (11·2%) 3 (7·3%)
Severe 0 0 1 (3·7%) 0 0 1 (0·8%) 0
Headache
Any 7 (29·2%) 5 (20·0%) 10 (37·0%) 7 (29·2%) 5 (20·0%) 34 (27·2%)* 6 (14·6%)
Mild 4 (16·7%) 4 (16·0%) 6 (22·2%) 4 (16·7%) 4 (16·0%) 22 (17·6%) 3 (7·3%)
Moderate 3 (12·5%) 1 (4·0%) 4 (14·8%) 3 (12·5%) 1 (4·0%) 12 (9·6%) 3 (7·3%)
Severe 0 0 0 0 0 0 0
Nasal congestion or runny nose
Any 5 (20·8%) 6 (24·0%) 4 (14·8%) 2 (8·3%) 2 (8·0%) 19 (15·2%) 3 (7·3%)
Mild 2 (8·3%) 4 (16·0%) 3 (11·1%) 1 (4·2%) 2 (8·0%) 12 (9·6%) 2 (4·9%)
Moderate 3 (12·5%) 2 (8·0%) 1 (3·7%) 1 (4·2%) 0 7 (5·6%) 1 (2·4%)
Severe 0 0 0 0 0 0 0
Sore throat
Any 2 (8·3%) 3 (12·0%) 1 (3·7%) 6 (25·0%) 1 (4·0%) 13 (10·4%) 4 (9·8%)
Mild 1 (4·2%) 3 (12·0%) 0 4 (16·7%) 1 (4·0%) 9 (7·2%) 3 (7·3%)
Moderate 1 (4·2%) 0 1 (3·7%) 2 (8·3%) 0 4 (3·2%) 1 (2·4%)
Severe 0 0 0 0 0 0 0
(Continues on next page)
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cohorts received three vaccinations, separated by about 
56 days each (ﬁ gure 1). 105 (63%) participants (83 vaccinees 
and 22 placebo recipients) agreed to participate in the 
protein boost substudy and received 90 μg inactivated 
subvirion H5N1 3·5–15·5 months after their last dose of 
Ad4-H5-Vtn vaccine or placebo (ﬁ gure 1). 88 household 
contacts, aged 18–61 years, took part in the study.
Ad4-H5-Vtn was not detected in any clinical specimen 
other than rectal swabs, with the exception of one 
vaccinee whose throat swab was positive for Ad4-H5-
Vtn by PCR (and conﬁ rmed by culture) only on day 7. All 
his other specimens were negative. He was and 
remained entirely asymptomatic. Shedding of the Ad4-
H5-Vtn was detected at day 14 in some vaccinees, 
particularly those who received lower doses (10⁷ VP–10⁹ 
VP). Thus, potentially, reactogenicity newly appearing 
during days 7–14 might have been missed, though we 
noted no pattern to suggest that vaccine-related adverse 
events occurred during this period. We identiﬁ ed no 
apparent relation of reactogenicity to dose for any 
speciﬁ c solicited symptom or fever (tables 1, 2). For both 
vaccine and placebo groups, the highest occurrence of 
reactogenicity was reported after the ﬁ rst dose. 
Headache was the only reactogenicity symptom reported 
more frequently in vaccinees than placebo recipients 
after the ﬁ rst vaccination (p=0·046; table 1). The 
cumulative frequency of abdominal pain, diarrhoea, 
and nasal congestion after all three vaccinations was 
signiﬁ cantly higher in vaccinees than placebo recipients 
(21 [16·8%] of 125 vs one [2·4%] of 41, p=0·017; 24 
[19·2%] of 125 vs two [4·9%] of 41, p=0·027; 41 [32·8%] 
of 125 vs six [14·6%] of 41, p=0·028; respectively; 
appendix). Symptoms were generally mild; none were 
dosage related or led to discontinuation of vaccine. After 
the H5N1 boost, systemic reactogenicity was much the 
same in Ad4-H5-Vtn and placebo recipients (appendix). 
Local reactogenicity after boost was more common in 
Ad4-H5-Vtn vaccinees: injection site pain (all mild) was 
reported by 17 (20·5%) of 83 vaccinees and none of 
22 placebo recipients (p=0·020). However, the 
occurrence of tenderness at the injection site was 
similar between groups:  24 (28·9%) of 83 vaccinees and 
ﬁ ve (22·7%) of 22 placebo recipients. Severe tenderness 
was reported in three vaccinees and no placebo 
recipients (appendix).
No discontinuations for toxic eﬀ ects occurred (ﬁ gure 1). 
Three participants had serious adverse events: hal-
lucinations 6 months after the last vaccination and 
norovirus-associated gastroenteritis in the vaccine group, 
and pancreatitis in the placebo group. None were judged 
to be related to the study.
Ad4-H5-Vtn was not detected by PCR analysis of any 
clinical sample or rectal or throat swabs from any 
household contacts. However, two (3·4%) of 58 house-
hold contacts of vaccinees, and one (3·3%) of 
30 household contacts of placebo recipients had 
asymptomatic seroconversions to Ad4.
Replication of the Ad4-H5-Vtn vaccine virus or so-
called vaccine take (Ad4-H5-Vtn detected in rectal 
swabs or seroconversion to Ad4, or both) increased 
with increasing dose (ﬁ gure 2). A dose-response 
association was especially apparent after the ﬁ rst 
vaccination, for which occurrence of take ranged from 
25% (six of 24) with 10⁷ VP to 84% (21 of 25) with 
Ad4-H5-Vtn vaccine recipients Placebo (n=41)
10⁷ VP (n=24) 10⁸ VP (n=25) 10⁹ VP (n=27) 10¹⁰ VP (n=24) 10¹¹ VP (n=25) All doses combined 
(n=125)
(Continued from previous page)
Cough
Any 2 (8·3%) 2 (8·0%) 1 (3·7%) 3 (12·5%) 0 8 (6·4%) 1 (2·4%)
Mild 2 (8·3%) 2 (8·0%) 0 3 (12·5%) 0 7 (5·6%) 1 (2·4%)
Moderate 0 0 1 (3·7%) 0 0 1 (0·8%) 0
Severe 0 0 0 0 0 0 0
Shortness of breath
Any 1 (4·2%) 0 1 (3·7%) 0 0 2 (1·6%) 0
Mild 0 0 0 0 0 0 0
Moderate 1 (4·2%) 0 1 (3·7%) 0 0 2 (1·6%) 0
Severe 0 0 0 0 0 0 0
Fever
Any 0 0 0 0 0 0 0
Mild 0 0 0 0 0 0 0
Moderate 0 0 0 0 0 0 0
Severe 0 0 0 0 0 0 0
Data are n (%) who reported that symptom at least once in the 7 days after the ﬁ rst dose. *The group comprised of all Ad4-H5-Vtn recipients reported signiﬁ cantly more 
headaches than did placebo recipients (p=0·046).
Table 1: Signs and symptoms of reactogenicity and highest severity level reported after ﬁ rst dose
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Ad4-H5-Vtn vaccine recipients Placebo (n=41)
10⁷ VP (n=24) 10⁸ VP (n=25) 10⁹ VP (n=27) 10¹⁰ VP (n=24) 10¹¹ VP (n=25) All doses combined 
(n=125)
Abdominal pain
Vaccination number
1 2/24 (8%) 3/25 (12%) 4/27 (15%) 3/24 (13%) 1/25 (4%) 13/125 (10%) 1/41 (2%)
2 2/23 (9%) 0/25 1/27 (4%) 2/19 (11%) 0/23 5/117 (4%) 0/40 
3 1/17 (6%) 1/24 (4%) 0/24 0/18 2/20 (10%) 4/103 (4%) 0/31 
Diarrhoea
Vaccination number
1 2/24 (8%) 3/25 (12%) 3/27 (11%) 5/24 (21%) 4/25 (16%) 17/125 (14%) 2/41 (5%)
2 2/23 (9%) 1/25 (4%) 1/27 (4%) 2/19 (11%) 1/23 (4%) 7/117 (6%) 0/40 
3 1/17 (6%) 1/24 (4%) 0/24 0/18 1/20 (5%) 3/103 (3%) 0/31 
Nausea or vomiting
Vaccination number
1 1/24 (4%) 1/25 (4%) 3/27 (11%) 1/24 (4%) 3/25 (12%) 9/125 (7%) 1/41 (2%)
2 1/23 (4%) 2/25 (8%) 1/27 (4%) 0/19 1/23 (4%) 5/117 (4%) 1/40 (3%)
3 0/17 1/24 (4%) 0/24 0/18 2/20 (10%) 3/103 (3%) 1/31 (3%)
Chills
Vaccination number
1 0/24 1/25 (4%) 0/27 1/24 (4%) 0/25 2/125 (2%) 0/41 
2 1/23 (4%) 2/25 (8%) 1/27 (4%) 0/19 0/23 4/117 (3%) 0/40 
3 0/17 1/24 (4%) 0/24 1/18 (6%) 0/20 2/103 (2%) 0/31 
Muscle or body aches
Vaccination number
1 1/24 (4%) 1/25 (4%) 4/27 (15%) 2/24 (8%) 3/25 (12%) 11/125 (9%) 1/41 (2%)
2 1/23 (4%) 2/25 (8%) 2/27 (7%) 1/19 (5%) 0/23 6/117 (5%) 1/40 (3%)
3 0/17 2/24 (8%) 0/24 2/18 (11%) 1/20 (5%) 5/103 (5%) 1/31 (3%)
Joint pain
Vaccination number
1 1/24 (4%) 0/25 2/27 (7%) 1/24 (4%) 1/25 (4%) 5/125 (4%) 1/41 (2%)
2 0/23 0/25 0/27 0/19 0/23 0/117 0/40 
3 0/17 0/24 0/24 1/18 (6%) 0/20 1/103 (1%) 0/31 
Tiredness
Vaccination number
1 6/24 (25%) 7/25 (28%) 6/27 (22%) 5/24 (21%) 4/25 (16%) 28/125 (22%) 5/41 (12%)
2 2/23 (9%) 0/25 3/27 (11%) 2/19 (11%) 0/23 7/117 (6%) 0/40 
3 2/17 (12%) 0/24 1/24 (4%) 2/18 (11%) 1/20 (5%) 6/103 (6%) 2/31 (6%)
Headache
Vaccination number
1 7/24 (29%) 5/25 (20%) 10/27 (37%) 7/24 (29%) 5/25 (20%) 34/125 (27%) 6/41 (15%)
2 2/23 (9%) 2/25 (8%) 6/27 (22%) 4/19 (21%) 2/23 (9%) 16/117 (14%) 5/40 (13%)
3 4/17 (24%) 3/24 (13%) 3/24 (13%) 3/18 (17%) 1/20 (5%) 14/103 (14%) 1/31 (3%)
Nasal congestion or runny nose
Vaccination number
1 5/24 (21%) 6/25 (24%) 4/27 (15%) 2/24 (8%) 2/25 (8%) 19/125 (15%) 3/41 (7%)
2 6/23 (26%) 2/25 (8%) 7/27 (26%) 2/19 (11%) 2/23 (9%) 19/117 (16%) 3/40 (8%)
3 3/17 (18%) 3/24 (13%) 2/24 (8%) 0/18 1/20 (5%) 9/103 (9%) 1/31 (3%)
Sore throat
Vaccination number
1 2/24 (8%) 3/25 (12%) 1/27 (4%) 6/24 (25%) 1/25 (4%) 13/125 (10%) 4/41 (10%)
2 2/23 (9%) 0/25 4/27 (15%) 3/19 (16%) 1/23 (4%) 10/117 (9%) 1/40 (3%)
3 3/17 (18%) 1/24 (4%) 2/24 (8%) 1/18 (6%) 1/20 (5%) 8/103 (8%) 0/31 
(Continues on next page)
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10¹¹ VP. Overall, 57 (46%) of 125 of vaccinees had PCR-
positive rectal swabs, with or without associated Ad4 
seroconversion. We identiﬁ ed PCR-positive swabs in 
roughly equal numbers in the lower dose cohorts 
(10⁷ VP–10⁹ VP) at both 7 days and 14 days and in the 
high-dose cohorts (10¹⁰ VP and 10¹¹ VP) almost 
exclusively at 7 days (appendix), consistent with a 
shorter incubation period in participants receiving 
high doses. Of the 57 vaccinees with at least one PCR-
positive rectal swab, an Ad4-H5-Vtn virus was detected 
by culture in 38 (67%). We identiﬁ ed no relation 
between dose and culture positivity. Occurrence of 
Ad4 sero conversion ranged from 29% to 96% and 
GMTs from 4 to 130 (ﬁ gure 2B).
Although cumulative take after the second vaccination 
showed much the same dose association as for the ﬁ rst 
vaccination, the greatest eﬀ ect of additional vaccinations 
was in the lower dose cohorts (10⁷ VP–10⁹ VP), in which 
participants without a take after the ﬁ rst or second 
administration subsequently had a take (ﬁ gure 2).
Interferon-γ T-cell response to recombinant H5 
haemagglutinin protein or peptide pools ranged from 38% 
(nine of 24 vaccinees) with 10⁷ VP to 70% (16 of 23 vaccines) 
with 10¹¹ VP, compared with only 5% (two of 41) of placebo 
recipients (ﬁ gure 2). Interleukin-2 responses were much 
the same (appendix). Vaccinees in the 10¹⁰ VP and 10¹¹ VP 
groups showed the largest overall response after the initial 
vaccination. Median response for interferon γ was 
232 spots per 10⁶ cells with 10¹¹ VP compared with 57 spots 
per 10⁶ cells with placebo (p<0·0001). Median response for 
interleukin 2 was 345 spots per 10⁶ cells with 10¹¹ VP 
compared with 111 spots per 10⁶ for placebo (p<0·0001). In 
specimens with suﬃ  cient blood remaining, pilot studies 
analysing intracellular cytokine production or CD4 and 
CD8 depleted ELISPOT assays showed that responses 
were predominantly induced by CD4-positive T cells (data 
not shown).
By contrast with the cellular response, haemagglutinin-
speciﬁ c antibody responses before boosting were scarce 
and of low titres (tables 3, 4). HAI seroconversion 
ranged from 4% to 19% among the vaccine cohorts, 
compared with 7% among placebo recipients 
(tables 3, 4). Only ﬁ ve vaccinees and no placebo 
recipients achieved seroprotection (HAI titre ≥40). 
However, after one boost with inactivated H5N1 vaccine, 
Ad4-H5-Vtn recipients had signiﬁ cantly higher 
occurrence of seroconversion than did placebo 
recipients: 80% for HAI and 67% for microneutralisation 
in vaccinees, compared with 36% and 33%, respectively, 
in placebo recipients (tables 3, 4; p=0·0003 for HAI, 
p=0·006 for microneutralisation). Across the ﬁ ve 
vaccine cohorts, occurrence of HAI seroconversion 
ranged from 67% to 100%; micro neutralisation sero-
conversion ranged from 56% to 80% (tables 3, 4). Post-
boost HAI GMT for all vaccine cohorts was 56 (range 
28–135), compared with 13 for the placebo group 
(tables 3, 4; p<0·0001 for all groups vs placebo; GMT 
10·7, 95% CI 5·5–20·9). Seroprotection ranged from 
61% to 89% in vaccine groups, compared with 18% for 
placebo (tables 3, 4). We identiﬁ ed evidence of 
heterologous (cross-clade) HAI response with the 
homologous prime and homologous boost. In a pilot 
substudy, all participants with post-boost HAI titres of 
80 or more were assessed for cross-clade responses. 
Ad4-H5-Vtn vaccine recipients Placebo (n=41)
10⁷ VP (n=24) 10⁸ VP (n=25) 10⁹ VP (n=27) 10¹⁰ VP (n=24) 10¹¹ VP (n=25) All doses combined 
(n=125)
(Continued from previous page)
Cough
Vaccination number
1 2/24 (8%) 2/25 (8%) 1/27 (4%) 3/24 (13%) 0/25 8/125 (6%) 1/41 (2%)
2 2/23 (9%) 1/25 (4%) 4/27 (15%) 0/19 0/23 7/117 (6%) 2/40 (5%)
3 3/17 (18%) 1/24 (4%) 1/24 (4%) 0/18 1/20 (5%) 6/103 (6%) 0/31 
Shortness of breath
Vaccination number
1 1/24 (4%) 0/25 1/27 (4%) 0/24 0/25 2/125 (2%) 0/41 
2 0/23 1/25 (4%) 0/27 0/19 0/23 1/117 (1%) 0/40 
3 1/17 (6%) 0/24 0/24 0/18 0/20 1/103 (1%) 1/31 (3%)
Fever
Vaccination number
1 0/24 0/25 0/27 0/24 0/25 0/125 0/41 
2 0/23 0/25 0/27 1/19 (5%) 0/23 1/117 (1%) 0/40 
3 0/17 1/24 (4%) 0/24 0/18 0/20 1/103 (1%) 0/31 
Data are n/N (%).
Table 2: Participants reporting reactogenicity signs or symptoms
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15 of the 16 vaccinees (and one of two placebo recipients) 
with post-boost HAI titres of 80 or more to 
A/Vietnam/2004 (clade 1) had seroprotective titres (HAI 
≥40) to A/Dk/Hunan/2002 (a clade 2.1 H5 virus), 
suggesting that Ad4-H5 clade 1 prime, followed by the 
subvirion clade 1 boost immunisation, induced 
suﬃ  cient heterologous antibody response to a clade 2.1 
H5 virus to predict protection against this subtype.
Plasma IgA ELISA seroresponse generally mirrored 
the HAI and microneutralisation response before 
boost, but the IgG ELISA response was more robust. In 
the highest dose cohort, 12 (50%) of 24 were IgG 
seropositive, compared with two (5%) of 39 in the 
placebo group. After-boost responses were strong, with 
100% responding to IgG in the highest dose cohort; 
50% (11 of 22) of placebo recipients were IgG 
seropositive after boost. Similar to serum ﬁ ndings, 
occurrence of IgG and IgA response in before-boost 
cervical, rectal, and nasal mucosal samples were low 
(data not shown). After boost, we noted that IgG 
responses in nasal mucosal samples were generally 
higher in vaccinees than in the placebo group (cervical 
and rectal specimens were not obtained post-boost; 
appendix).
Ad4 immunity at baseline (neutralising antibody >6) 
was noted in 35 (28%) of 125 of vaccinees and was 
associated with lower occurrence of vaccine take, pre-
boost cellular immune response, and post-boost HAI 
and microneutralisation antibody response (ﬁ gure 3). 
This eﬀ ect was largely overcome in the high-dose cohorts 
(10¹⁰ VP and 10¹¹ VP). Similarly, high doses were more 
likely to outstrip the response from the initial 
vaccination: recurrence of vaccine virus replication in 
participants who had had a take with their previous 
vaccination increased with increasing dose. Recurrence 
(second take) of Ad4-H5-Vtn replication after second or 
third vaccination occurred in 32 (36%) of 89 vaccinees 
who had had a take during a previous vaccination, 
ranging from 14% (three of 21) with 10⁸ VP to 65% (15 of 
23) with 10¹¹ VP.
0
20
40
60
80
100
Pa
rt
ici
pa
nt
s (
%
)
50%
60%
78% 79%
96%
0
20
40
60
80
100
Pa
rt
ici
pa
nt
s (
%
)
50%
60%
78% 79%
96%
0
20
40
60
80
100
Pa
rt
ici
pa
nt
s (
%
)
5%
38%
48%
52%
61%
70%
100
200
300
400
SF
C/
10
6  c
el
ls
0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 30 1 2 3
107 VP 108 VP 109 VP 1010 VP 1011 VP
Ad4-H5-Vtn vaccine group
107 VP 108 VP 109 VP 1010 VP 1011 VP
Ad4-H5-Vtn vaccine group
107 VP 108 VP 109 VP 1010 VP 1011 VP
Ad4-H5-Vtn vaccine group
Placebo
107 VP 108 VP 109 VP 1010 VP 1011 VP
Ad4-H5-Vtn vaccine group
Placebo
Dose number
A B
C D
1 vaccination
2 vaccinations
3 vaccinations
1 vaccination
2 vaccinations
3 vaccinations
PCR+
Both PCR and Ad4
Ad4 seroconversion
Median
Figure 2: Vaccine take and cellular immune response by vaccination and by median number of ELISPOT forming cells
Cumulative vaccine take (A) deﬁ ned as Ad4 seroconversion or a PCR-positive rectal swab at 7 days or 14 days after vaccination, or both; cumulative percentage of 
participants with at least one take after one, two, and three Ad4-H5-Vtn vaccinations. Vaccine take components (B) partitioned to show proportion of participants 
who had PCR-positive rectal swab, Ad4 seroconversion, or both after any vaccination; data not available for placebo recipients, who were not assessed for shedding of 
vaccine virus. Cumulative percentage of participants with an ELISPOT interferon-γ response (C), deﬁ ned as 80 or more spot forming cells (SFC) and four-times greater 
than baseline SFC, after one, two, and three vaccinations. Median number of ELISPOT SFC/10⁶ cells at baseline and after each vaccination (D); error bars show IQR. 
ELISPOT=enzyme-linked immunosorbent spot.
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Discussion
The Ad4-H5-Vtn vector vaccine was well tolerated; 
symptoms of reactogenicity were generally mild and 
resolved within 7 days of vaccination. No serious 
treatment-related adverse events occurred. Ad4-H5-Vtn 
was not detected by PCR analysis of samples from 
household contacts of participants. After three vac-
cinations, haemagglutinin-speciﬁ c antibody responses to 
Ad4-H5-Vtn vaccine recipients Placebo
10⁷ VP 10⁸ VP 10⁹ VP 10¹⁰ VP 10¹¹ VP All doses 
combined
Pre-boost vaccinations n=24 n=25 n=27 n=23 n=24 n=123 n=41
Day 56 (one vaccination)
% seroconverted (95% CI) 0% (0–14) 4% (0–20) 7% (1–24) 0% (0–15) 4% (0–21) 3% (1–8) 5% (1–17)
GMT (95% CI) 5 (NC) 6 (5–7) 6 (5–6) 5 (5–6) 6 (5–8) 6 (5–6) 5 (5–5)
Day 112 (two vaccinations)
% seroconverted (95% CI) 4% (0–21) 8% (1–26) 15% (4–34) 4% (0–22) 13% (3–32) 9% (5–15) 5% (1–17)
GMT (95% CI) 5 (5–6) 7 (5–10) 6 (5–7) 6 (5–7) 6 (5–8) 6 (6–7) 5 (NC)
Day 140 (three vaccinations)
% seroconverted (95% CI) 4% (0–21) 12% (3–31) 19% (6–38) 4% (0–22) 13% (3–32) 11% (6–17) 7% (2–20)
GMT (95% CI) 5 (5–6) 8 (5–12) 6 (5–7) 5 (5–6) 7 (5–9) 6 (5–7) 5 (5–6)
Boost vaccination n=13 n=18 n=18 n=15 n=19 n=83 n=22
% seroconverted (95% CI) 69% (39–91) 78% (52–94) 67% (41–87) 80% (52–96) 100% (82–100) 80% (69–88)* 36% (17–59)
% seroprotected (95% CI) 62% (32–86) 67% (41–87) 61% (36–83) 80% (52–96) 89% (67–99) 72% (61–82)† 18% (5–40)
GMT (95% CI) 28 (12–64) 48 (24–94) 34 (16–74) 77 (38–153) 135 (89–205) 56 (42–76)† 13 (7–21)
For HAI, pre-boost seroconversion is a four-times or greater rise compared with baseline. Post-boost seroconversion is a four-times or greater rise compared with the titre 
obtained just before boost vaccination. Seroprotection is a titre ≥40. Pre-boost percentages are cumulative—eg, a participant who seroconverted by day 56 is counted as 
seroconverted at days 112 and 140 also. Pre-boost percentages are calculated from participants (n) who had a baseline result and at least one post-vaccination result. 
Post-boost percentages are calculated from participants (n) who had both pre-boost and post-boost results. Missing post-vaccination results are counted as negative 
responses. GMTs are calculated from all data available at the indicated timepoint. HAI=haemagglutination-inhibition. GMT=geometric mean titre. NC=not calculable. 
*p=0·0003. †p<0·0001.
Table 3: Cumulative seroconverted by HAI and GMT after each vaccination
Ad4-H5-Vtn vaccine recipients Placebo
10⁷ VP 10⁸ VP 10⁹ VP 10¹⁰ VP 10¹¹ VP All doses 
combined
Pre-boost vaccinations n=24 n=25 n=27 n=21 n=24 n=121 n=40
Day 56 (one vaccination)
% seroconverted (95% CI) 4% (0–21) 4% (0–20) 0% (0–13) 5% (0–24) 0% (0–14) 2% (1– 7) 3% (0–13)
GMT (95% CI) 5 (NC) 7 (6–9) 7 (6–9) 6 (5–8) 6 (5–6) 6 (6–7) 6 (5–7)
Day 112 (two vaccinations)
% seroconverted (95% CI) 4% (0–21) 4% (0–20) 7% (1–24) 5% (0–24) 8% (1–27) 6% (2– 12) 3% (0– 13)
GMT (95% CI) 5 (5–6) 6 (5–7) 9 (7–11) 6 (5–6) 7 (5–8) 6 (6–7) 6 (5–6)
Day 140 (three vaccinations)
% seroconverted (95% CI) 4% (0–21) 4% (0–20) 7% (1–24) 5% (0–24) 13% (3–32) 7% (3– 13) 3% (0–13)
GMT (95% CI) 5 (NC) 6 (5–8) 9 (7–11) 6 (5–7) 7 (6–9) 7 (6–7) 6 (5–7)
Boost vaccination n=13 n=18 n=18 n=15 n=18 n=82 n=21
% seroconverted (95% CI) 62% (32–86) 67% (41–87) 56% (31–78) 80% (52–96) 72% (47–90) 67% (56–77)* 33% (15–57)
% seroprotected (95% CI) 54% (25–81) 50% (26–74) 56% (31–78) 60% (32–84) 50% (26–74) 54% (42–65)† 14% (3–35)
GMT (95% CI) 48 (22–103) 46 (22–95) 45 (18–112) 97 (38–251) 42 (26–69) 52 (37–72)‡ 14 (9–22)
For H5 haemagglutinin microneutralisation, pre-boost seroconversion is a four-times or greater rise compared with baseline. Post-boost seroconversion is a four-times or 
greater rise compared with the titre obtained just before boost vaccination. Seroprotection is a titre ≥40. Pre-boost percentages are cumulative—eg, a participant who 
seroconverted by day 56 is counted as seroconverted at days 112 and 140 also. Pre-boost percentages are calculated from participants (n) who had a baseline result and at 
least one post-vaccination result. Post-boost percentages are calculated from participants (n) who had both pre-boost and post-boost results. Missing post-vaccination 
results are counted as negative responses. GMTs are calculated from all data available at the indicated timepoint. HAI=haemagglutination-inhibition. GMT=geometric mean 
titre. NC=not calculable. *p=0·006. †p=0·0007. ‡p=0·0001. 
Table 4: Cumulative seroconverted by H5 haemagglutinin microneutralisation and GMT after each vaccination
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all doses were scarce and of low titres, with HAI sero-
conversion ranging from 4% to 19% among the vaccine 
cohorts, compared with 7% among placebo recipients. 
However, after one inactivated parenteral H5N1 
immunisation, HAI seroconversion occurred in 80% of 
participants (100% in the highest-dose cohort), compared 
with 36% of placebo recipients, and GMT was signiﬁ cantly 
higher in participants who had been primed with Ad4-
H5-Vtn than in those who had received placebo  (panel).
The Ad4-H5-Vtn vector was bioengineered by partial 
deletion in the E3 region and insertion of the 
H5 haemagglutinin gene. The function of the E3 region 
in Ad4 is unknown, but, on the basis of strong E3 homology 
with Ad5, it is thought to be important in modulation of 
host-antiviral responses.22 Since Ad4 does not replicate in 
non-human animals except chim panzees,23 replication 
was assessed in human cell lines before we made an 
investigational new drug application and was shown to be 
attenuated compared with un modiﬁ ed Ad4.12 Nevertheless, 
the recorded occur rence of Ad4 seroconversion and GMTs 
in both Ad4 sero negative and seropositive Ad4-H5-Vtn 
recipients with doses of 10⁹ VP–10¹¹ VP (appendix) are 
much the same or higher than in the US military Ad4/Ad7 
vaccine phase 1 study.13 At these high doses, Ad4-H5-Vtn 
induced haemagglutinin-speciﬁ c cellular responses and 
primed for HAI antibody responses, even in participants 
with pre-existing Ad4 immunity.
The Ad4-H5-Vtn vaccine also resembled the US military 
Ad4 vaccine with respect to safety and a low rate of 
transmissibility.11,24–26 Although asymptomatic trans-
mission to intimate household contacts and children had 
been noted in studies before licensure, the US military 
Ad4 vaccine did not seem to be transmitted among 
military recruits.11,24–26 In our study of Ad4-H5-Vtn, no 
dose limiting or notable toxic eﬀ ects were identiﬁ ed with 
doses ranging from 10⁷ VP to 10¹¹ VP. All household 
contacts were enrolled into the study and monitored for 
potential acquisition of Ad4-H5-Vtn infection. No 
conﬁ rmed transmission to these contacts occurred, 
although asymptomatic seroconversion to Ad4 was 
recorded in two contacts of vaccinees and one contact of a 
placebo recipient. These were presumed sero conversions 
to wild-type Ad4, since Ad4-H5-Vtn was not detected in 
throat or rectal swabs of these three household contacts, 
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Figure 3: Eﬀ ect of pre-existing Ad4 immunity on occurrence of take, cellular immune response before boost, and seroconversion by HAI and H5 
haemagglutininin microneutralisation after boost
For vaccine take (A), deﬁ ned as Ad4 seroconversion or a PCR-positive rectal swab at 7 or 14 days after vaccination, or both, bar height represents the cumulative 
percentage of participants with a take at any time before study completion or receipt of boost vaccination. Analogous percentages for ELISPOT interferon-γ response 
before boost, deﬁ ned as 80 or more spot forming cells (SFC) and four-times greater than baseline SFC, are shown (B). HAI seroconversion after boost (C) and H5 
haemagglutinin microneutralisation (D) required a four-times rise compared with the last result before boost. The number of responders and the number of participants 
with evaluable samples are given above each bar. Pre-existing Ad4 immunity was deﬁ ned as an Ad4 microneutralisation titre greater than 6 before initial vaccination. 
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but seroconversion attributable to Ad4-H5-Vtn infection 
cannot be ruled out in the household contacts of the two 
vaccinees. Transmission to contacts of vaccinees is always 
a potential concern for live vaccines. Although the safety 
record of the US military Ad4 and Ad7 vaccines, including 
safety in contacts of vaccinees,11,24–26 and the absence of 
conﬁ rmed trans mission in our study provide reassurance, 
assess ment of trans missibility to, and safety in, vulnerable 
contacts will require further studies.
The Ad4-H5-Vtn vaccine induced haemagglutinin-
speciﬁ c cellular immune responses but only primed for 
haemagglutinin-speciﬁ c antibody responses. However, 
after one inactivated H5N1 parenteral vaccine boost, 
we noted substantial HAI and neutralising antibody 
responses with occurrence of seroconversion and GMTs 
higher than achieved with unadjuvanted, inactivated 
H5N1 vaccines.14,27 For example in another study,14 after 
two doses of 90 μg inactivated H5N1 subvirion vaccine 
only 58% of participants achieved the prespeciﬁ ed 
protective HAI titre of 1/40 or more and 57% sero-
converted. By contrast, we showed that after priming with 
Ad4-H5-Vtn and boosting with inactivated H5N1 vaccine, 
post-boost seroprotection and seroconversion were 80% 
and 80% with 10¹⁰ VP and 89% and 100% with 10¹¹ VP. 
These proportions are higher28 or similar29–31 to 
seroprotection rates for adjuvanted H5N1 vaccines or 
DNA priming followed by inactivated H5N1 boosting.32 In 
the DNA priming study,32 post-boost antibody responses 
were much the same, irrespective of whether vaccinees 
received one or two priming doses. Although the H5N1 
boost was given mostly to volunteers who had received all 
three doses of the oral Ad4-H5-Vtn, the pattern of cellular 
immune response and vaccine take, both occurring 
predominantly after the ﬁ rst Ad4-H5-Vtn administration, 
suggest that one oral dose would have been suﬃ  cient for 
priming. A phase 2 study to conﬁ rm that one dose of Ad4-
H5-Vtn is suﬃ  cient to prime for robust post-boost 
antibody responses, to investigate dosing of boost vaccine, 
and to assess the potential for broadening of response by 
cross-clade boosting, is being planned. Although 
speculation about the relative advantages and 
disadvantages of the oral Ad4 replicating vector approach 
versus DNA or replication-defective vectors might be 
premature, potential advantages, such as ease and reduced 
costs both of storage and of self-administration for an oral 
vaccine formulated as a capsule or tablet might be 
important in a national or worldwide response to an avian 
inﬂ uenza pandemic. Though safety concerns about 
replicating vectors exist, the safety of the parent Ad4 
vaccine virus, well established over many years by the US 
military,11 provides some reassurance.
The proﬁ le of immune response to the oral Ad4-H5-
Vtn prime—ie, low occurrence of HAI or neutralising 
antibody responses, but signiﬁ cant H5 haemagglutinin-
speciﬁ c cellular responses—resembles responses to 
live-attenuated H5N1, H5N2, and H6N1 intranasal 
candidate vaccines.33–35 We do not know whether, in the 
absence of haemagglutinin-protein boosting, the 
predominantly cellular immune response induced by 
Ad4-H5-Vtn, or a rapid anamnestic antibody response 
on exposure to H5N1, would be suﬃ  cient to protect 
against H5N1 infection or disease. The correlates of 
protection for live-attenuated seasonal inﬂ uenza vaccine 
are not well understood, particularly in children, and 
some reports suggest protection is mediated by local 
mucosal, cellular immune responses, or both, and that 
antibody titres much higher than the conventional HAI 
titre of at least 1/40 are required.36–38 Thus, we do not 
know whether one or several doses of the Ad4-H5-Vtn 
would be protective without parenteral boost, or whether 
the antibody response engendered by a prime-boost ap-
proach would be protective. Nevertheless, on the basis 
of our results, we might be able to infer that for 
pandemic H5N1 inﬂ uenza, one oral Ad4-H5 priming 
dose, fol lowed by a parenteral boost, would give better 
antibody response rates than two doses of inactivated 
vaccine, and, unlike the conventional parenteral 
vaccines, induce a robust cellular immune response. 
Potential beneﬁ ts, such as a reduction of the number of 
doses of inactivated pandemic inﬂ uenza vaccine 
required to be manufactured in a short time, and 
possibly prepandemic priming, have been suggested for 
the prime-boost approach.39
A possible reason why replicating Ad4-H5-Vtn by 
itself did not induce a good haemagglutinin-speciﬁ c 
antibody response is that the H5 haemagglutinin anti gen 
Panel: Research in context
Systematic review
We searched the medical literature (PubMed, literature cited in relevant publications) for 
clinical studies of replication-competent vector vaccines, avian inﬂ uenza vaccines, and Ad4 
or Ad7 vaccines. The PubMed search used the terms “pandemic inﬂ uenza”, “replication 
competent vector”, “adenovirus 4”, and “vector vaccine”; it was not limited by date or 
language. The date of the last search was Feb 21, 2012. We noted that few replicating vector 
vaccines have progressed to clinical assessment, and that most, while perhaps priming and 
inducing a cellular immune response to transgene expressed antigens, did not induce 
robust antibody responses. We noted that H5N1 vaccines, either inactivated or live 
attenuated, generally did not induce robust antibody responses compared with inﬂ uenza 
vaccines, either seasonal or other avian inﬂ uenza strains, such as H9N2 or H7N3.
Interpretation
As far as we are aware, our study is the ﬁ rst clinical trial of a replication-competent Ad4 
vector vaccine for any indication, and one of the few replication-competent vector clinical 
studies for inﬂ uenza. We conﬁ rmed that the orally administered Ad4 H5N1 vector vaccine 
seemed to have a safety proﬁ le, including low transmissibility, similar to the parent Ad4 
vaccine currently used by the US military. Similar to other vector vaccines, the Ad4 H5N1 
vector induced a cellular immune response but only minimum antibody response. 
However, one boost with inactivated H5N1 vaccine led to robust haemagglutination 
inhibition and H5N1 neutralising antibody responses. This study provides evidence 
supporting the oral replicating Ad4 vector prime-inactivated boost as a vaccine approach 
for pandemic inﬂ uenza, and potentially other infections for which both cellular and 
antibody responses are needed. However, conﬁ rmatory studies will be needed to better 
assess doses and intervals between prime and boost.
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intrinsically is a poor immunogen, and that an Ad4 vector 
with a diﬀ erent transgene encoded antigen might have 
induced robust antibody responses without boost. 
Experience with other avian inﬂ uenza vaccines is 
consistent with poor intrinsic immunogenicity of the 
H5 haemagglutinin. Two dose regimens of live-
attenuated versions of H5N1 or H5N2 induced HAI 
antibody responses in only 10%34 or 20%33 of volunteers, 
whereas analogous live-attenuated avian inﬂ uenza H9N2 
and H7N3 vaccines had responses as high as 92% and 
62%, respectively.40,41
Cell tropism attributable to inherent or unique 
properties of the Ad4 vector virus remains another 
possible explanation. However, in chimpanzees in which 
Ad4 vectors replicate to a limited extent, they have 
induced good HIV-Env antibody responses,42 and in 
other animals, including non-human primates, in which 
Ad4 vectors perform as a replication-defective vector, 
robust HIV-Env antibody or HAI responses have also 
been induced.12,43 Another possible explanation is that 
replicating vectors might inherently express their trans-
genes in a manner not conducive to direct stimulation of 
antibody. Analogous results (ie, marginal antibody 
response to the transgene encoded antigen but 
signiﬁ cant priming for subsequent boost) were noted 
with a replication-competent vaccinia vector expressing 
HIV gp160,7,8 but safety issues with vaccinia have 
precluded its wide development.44 Other replicating viral 
vectors have induced cellular responses, but only poor 
antibody responses in clinical trials.6
Several potential explanations exist for the low 
haemagglutinin-speciﬁ c binding antibody and sporadic 
HAI responses, despite haemagglutinin-speciﬁ c cellular 
responses. Oral admin istration of the Ad4-H5-Vtn vector 
eﬃ  ciently primed for HAI antibody responses as 
evidenced by the robust anti body responses to boosting 
with inactivated parenteral H5N1 vaccine. Since 
heamagglutinin-speciﬁ c cellular responses were 
induced, which would presumably provide helper 
functions, and low level haemagglutinin-speciﬁ c binding 
antibody was also generated, it is likely that suﬃ  cient 
antigen might not have been available for robust B-cell 
activation and maturation. Insuﬃ  cient haem agglutinin 
antigen presentation might have several causes 
including insuﬃ  cient amounts of expression, sub-
optimum conformation (which would have a lesser 
eﬀ ect on T-cell responses), lack of transport of expressed 
antigen to locations available for sampling by antigen-
presenting cells and B cells, or degradation of the 
antigen. Further human experience with these Ad4 
recombinant vectors expressing either Bacillus anthracis 
protective antigen, HIV-1 mosiac gag, or HIV-1 envelope 
will come from phase 1 trials in 2013, and the results 
might show whether immune proﬁ les noted in this trial 
were the result of the characteristics of the H5 antigen or 
inherent properties of the oral administration of these 
replication-competent vectors.
Irrespective of the cause for the poor antibody response 
after oral administration of the Ad4-H5-Vtn vaccine, its 
immunogenicity—vector induction of a cellular im mune 
response but with antibody response only after 
heterologous protein boosting—is the proﬁ le that was 
noted after immunisation with a canarypox vector and 
rEnv boost in the only HIV vaccine trial to have shown 
any, if only modest, eﬃ  cacy.45 A vaccination regimen 
consisting of priming by a replicating Ad4 HIV-Env 
vector, followed by rEnv parenteral boosting might 
provide a similar or better immunological proﬁ le, 
particularly if oral priming by adenovirus leads to a 
mucosal cellular response as shown in animals.1,46,47 
Replication-competent vector vaccines have, for many 
years, been proposed as potentially being the best avenue 
to a successful HIV-1 vaccine, since they are deemed to 
approximate more closely the features of live-attenuated 
vaccines, induce HIV-speciﬁ c immune responses at the 
virus mucosal entry point, and might have a stronger 
immunogenicity than non-replicating vectors by in-
duction of more potent innate and adaptive immune 
responses.2 Ad4 vaccine vectors expressing HIV-1 Env and 
Gag, to be followed by rEnv boost are currently scheduled 
for phase 1 clinical trials in 2013. Replicating Ad4 vector 
vaccines might also be eﬀ ective in prime-boost regimens 
for other infections such as malaria, herpes simplex virus, 
and cytomegalovirus, for which both cellular and antibody 
responses seem to be needed for protection.
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